No abstract

BackgroundThere is still a substantial unmet need for less invasive and lower-cost blood-based biomarkers to detect brain Alzheimer’s disease (AD) pathology. This study is aimed to determine whether quantification of plasma tau phosphorylated at threonine 181 (p-tau181) is informative in the diagnosis of AD.MethodsWe have developed a novel ultrasensitive immunoassay to quantify plasma p-tau181, and measured the levels of plasma p-tau181 in three cohorts.ResultsIn the first cohort composed of 20 AD patients and 15 age-matched controls, the plasma levels of p-tau181 were significantly higher in the AD patients than those in the controls (0.171 ± 0.166 pg/ml in AD versus 0.0405 ± 0.0756 pg/ml in controls, p = 0.0039). The percentage of the subjects whose levels of plasma p-tau181 exceeded the cut-off value (0.0921 pg/ml) was significantly higher in the AD group compared with the control group (60% in AD versus 16.7% in controls, p = 0.0090). In the second cohort composed of 20 patients with Down syndrome (DS) and 22 age-matched controls, the plasma concentrations of p-tau181 were significantly higher in the DS group (0.767 ± 1.26 pg/ml in DS versus 0.0415 ± 0.0710 pg/ml in controls, p = 0.0313). There was a significant correlation between the plasma levels of p-tau181 and age in the DS group (R2 = 0.4451, p = 0.0013). All of the DS individuals showing an extremely high concentration of plasma p-tau181 (> 1.0 pg/ml) were older than the age of 40. In the third cohort composed of 8 AD patients and 3 patients with other neurological diseases, the levels of plasma p-tau181 significantly correlated with those of CSF p-tau181 (R2 = 0.4525, p = 0.023).ConclusionsWe report for the first time quantitative data on the plasma levels of p-tau181 in controls and patients with AD and DS, and these data suggest that the plasma p-tau181 is a promising blood biomarker for brain AD pathology. This exploratory pilot study warrants further large-scale and well-controlled studies to validate the usefulness of plasma p-tau181 as an urgently needed surrogate marker for the diagnosis and disease progression of AD.Electronic supplementary materialThe online version of this article (doi:10.1186/s13024-017-0206-8) contains supplementary material, which is available to authorized users.

Neural precursor cells (NPCs) in the mouse neocortex generate various neuronal and glial cell types in a developmental stage–dependent manner. Most NPCs lose their neurogenic potential during development, although the underlying mechanisms of this process are not fully understood. We found that the chromatin of mouse NPCs gradually becomes more condensed and less dynamic on a global scale during neocortical development. Furthermore, we found high mobility group A (HMGA) proteins to be essential for the open chromatin state of NPCs at early developmental stages. Knockdown of HMGA proteins in early-stage NPCs reduced their neurogenic potential. Conversely, overexpression of HMGA proteins conferred neurogenic potential on late-stage NPCs, an effect that was antagonized by coexpression of a histone H1 mutant that inhibits chromatin opening. Thus, HMGA proteins contribute to the neurogenic potential of NPCs in the early stages of neocortical development, possibly through induction of an open chromatin state.

No abstract

Background and aims: Many lines of evidence suggest that T helper cell type 1 (Th1) immune responses predominate in Crohn's disease (CD). Recently, a novel transcription factor T-box expressed in T cells (T-bet) has been reported as the master regulator of Th1 development. This study was designed to investigate the role of T-bet and proinflammatory cytokines in Th1 mediated immunopathology in CD. Materials: CD4+ lamina propria mononuclear cells (LPMCs) were isolated from surgically resected specimens (CD, n = 10; ulcerative colitis (UC), n = 10; normal controls (NL), n = 5).

Highlights d Setd1a (+/À) mice mimicking a frameshift mutation of a SCZ patient are generated d Setd1a (+/À) mice display various abnormal behaviors relevant to features of SCZ d Postsynaptic SETD1A is crucial for excitatory synaptic function and structure d Setd1a in layer 2/3 pyramidal neurons of mPFC is involved in mouse social behavior

Methyl methacrylate, a cyclic olefin, and two alk-1-enes are efficiently converted into their corresponding epoxides by nt-chloroperbenzoic acid a t elevated temperatures in the presence of a small amount of a radical inhibitor, which prevents thermal decomposition of the peracid.:@-H20Hwas considered ; however, thermal decomposition of the peracid becomes a problem and the possibility that it might be suppressed in the presence of some radical inhibitor was investigated.?IN the course of an investigation directed towards a total synthesis of tetrodotoxin,l conversion of the olefin (I) into the epoxide (11) was required. This seemingly easy step turned out to be difficult because the double bond in the L b Ht) iiF ' olefin (I) has exceptionally poor reactivity towards peracids AC ( 1 ) such as m-chloroperbenzoic acid, peracetic acid, and performic acid. Epoxidation a t an elevated temperature Ac (II) t T. M. Luong and D. Lefort observed that the decomposition of perbenzoic acid in cyclohexane at 80 "C is suppressed in the presence However, these inhibitors are not efiective enough for the of 9-benzoquinone or hydroquinone (Bull. Soc. chim. France, 1962, 827). present purpose.$ We are indebted to Sumitomo Chemical Co., Ltd., for gifts of the radical inhibitors.3 Epoxidation of (I) with m-chloroperbenzoic acid (excess) a t 90 "C in the absence of the radical inhibitor gave a complex mixture.

Neural precursor cells (NPCs) in the mammalian neocortex generate various neuronal and glial cell types in a developmental stage-dependent manner. Most neocortical NPCs lose their neurogenic potential after birth. We have previously shown that high-mobility group A (HMGA) proteins confer the neurogenic potential on early-stage NPCs during the midgestation period, although the underlying mechanisms are not fully understood. In this study, we found that HMGA2 promotes the expression of insulin-like growth factor 2 mRNA-binding protein 2 (IMP2, Igf2bp2) in neocortical NPCs. The level of IMP2 was indeed high in earlystage NPCs compared with that in late-stage NPCs. Importantly, over-expression of IMP2 increased the neurogenic potential and suppressed astrocytic differentiation of late-stage NPCs, whereas knockdown of IMP2 promoted astrocytic differentiation and reduced the neurogenic potential of early-stage neocortical NPCs without overtly affecting cell proliferation. Our results thus identified IMP2 as a developmental stage-dependent regulator of the differentiation potentials of NPCs in the mouse neocortex.